A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease.
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerBulked sample analysis in genetics, genomics and crop improvementApplications of targeted proteomics in systems biology and translational medicineMass spectrometry for translational proteomics: progress and clinical implicationsImpact of Next-Generation Sequencing (NGS) technology on cardiovascular disease researchDifferential diagnosis of azoospermia with proteomic biomarkers ECM1 and TEX101 quantified in seminal plasmaMass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimensPlasma proteomic analysis of stable coronary artery disease indicates impairment of reverse cholesterol pathwayIdentification of direct target engagement biomarkers for kinase-targeted therapeuticsA framework for the study of multiple realizations: the importance of levels of analysisProteomic analysis of effluents from perfused human heart for transplantation: identification of potential biomarkers for ischemic heart damageOpen access integrated therapeutic and diagnostic platforms for personalized cardiovascular medicineBioengineering silicon quantum dot theranostics using a network analysis of metabolomic and proteomic data in cardiac ischemia.Mycobacterial Esx-3 requires multiple components for iron acquisition.The use of biophysical proteomic techniques in advancing our understanding of diseases.Proteomics in heart failure: top-down or bottom-up?Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studiesCirculating proteolytic signatures of chemotherapy-induced cell death in humans discovered by N-terminal labeling.Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.A blood-based proteomic classifier for the molecular characterization of pulmonary nodules.Detection of Mycobacterium tuberculosis peptides in the exosomes of patients with active and latent M. tuberculosis infection using MRM-MSMinimum data elements for research reports on CFSPlatform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation.Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics.Academic College of Emergency Experts in India's INDO-US Joint Working Group and OPUS12 Foundation Consensus Statement on Creating A Coordinated, Multi-Disciplinary, Patient-Centered, Global Point-of-Care Biomarker Discovery NetworkEnsembles of protein termini and specific proteolytic signatures as candidate biomarkers of disease.Large-scale inference of protein tissue origin in gram-positive sepsis plasma using quantitative targeted proteomics.N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications.Computational biomarker pipeline from discovery to clinical implementation: plasma proteomic biomarkers for cardiac transplantation.Novel isotopic N,N-dimethyl leucine (iDiLeu) reagents enable absolute quantification of peptides and proteins using a standard curve approachParallel workflow for high-throughput (>1,000 samples/day) quantitative analysis of human insulin-like growth factor 1 using mass spectrometric immunoassay.Recent developments in proteomic methods and disease biomarkers.Relative quantification of several plasma proteins during liver transplantation surgery.Antibody colocalization microarray: a scalable technology for multiplex protein analysis in complex samples.Sample displacement chromatography as a method for purification of proteins and peptides from complex mixturesEnhancing bottom-up and top-down proteomic measurements with ion mobility separationsAdvancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics.Large-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma.Multiplexed, Quantitative Workflow for Sensitive Biomarker Discovery in Plasma Yields Novel Candidates for Early Myocardial Injury.High-throughput fractionation of human plasma for fast enrichment of low- and high-abundance proteins
P2860
Q26738703-EA3E0B70-5055-4408-AF4B-1A558936F8E4Q26753827-5623E9EB-DE6B-4364-B869-359912F562E2Q26852271-C97AE29C-1FAD-433D-A4D3-DB48660AD323Q26995497-9FFC6AA9-F3B1-4622-9D0F-1E14921027BBQ27025831-2312AC94-5578-463D-905C-DE2C54059F5DQ28302387-70F17D40-9585-472E-A13E-145A48950C2AQ28307595-1A653F36-98F7-4FFE-BF33-4283DBF3C997Q28397909-D3548A68-B4F1-46D9-92AD-32E31C5D58ECQ28477593-E9D4C921-4B3A-4A73-BB83-ADA2391349E1Q28742360-DFBF4B9A-63C4-4C00-BF66-80B5FDF16B1FQ30426945-A0182493-25B6-4EAD-A8AF-45D429977098Q30487537-518131A1-70AD-4646-A974-A4C6931C2ECCQ30665892-AC1B53BF-14FF-4F20-B14E-82E4D3CAC555Q33569516-C05E8F14-9E95-47D8-9649-500803C94633Q33639590-0E2B959F-3988-4730-B295-499484A63B2DQ33680476-63008365-C02D-42EF-A9E5-9054B18C07FFQ33688759-99AA14E3-C22E-4B91-BF6A-37879E984EE9Q33694691-5E7AE880-F6D4-4FFF-8317-E55892A78908Q33850616-15C380AA-F053-40FB-8C79-2A77D186F8C2Q33968948-2BB4C8EC-E146-409C-9F7E-BA6F73DB0062Q33982504-2DAF541D-0447-47AC-A395-2B794AFE265EQ34151020-9EF6D0AB-3135-418C-A644-FE07C6BAC3ECQ34210429-01210C6C-EE22-4C58-A5C2-980C1AE3617DQ34333925-3BE3DEFF-D40B-4AFC-AEE4-CB948F2D6ADEQ34357303-2FFD3CDD-5C07-4BE2-91F1-C24E7AAC7599Q34402330-02C953D8-8E7F-4BF3-95B5-018716AD7E8CQ34507442-AF108BB2-9F63-49A7-AEE2-B1C2E7720983Q34585592-5EBB9408-492E-4BE3-B52A-9BF09D5F66C7Q34671668-CF065392-A1C3-4149-B095-1FC92330FCD6Q34772405-83B4E35F-5A09-4A65-A093-50EA154D9CABQ35130223-DC456D41-CD8A-4BA8-8D99-11D0F711EB29Q35197167-AC7CCCDE-4054-4084-A774-1F3725403637Q35610458-AF958E3F-F6FB-4F0D-9D90-B6DB08AC6689Q35878752-EEE0E320-139D-49DD-B1B3-7CE8494736E3Q35923124-B4BCB4E7-CE67-4283-903B-3C546DBDD6D9Q35945797-8A2E5083-52FE-4E2D-BFAA-FB609E570CE0Q36031629-CABF7C5F-1291-45CA-AD1F-F36D9B1551CBQ36040373-DFA3829C-3263-4781-9D26-BFC797F68B89Q36040379-B0EB4F47-2D30-4327-8A6D-EFF38F258F0FQ36162778-D0634235-8BC2-426A-AD8E-333090354455
P2860
A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A pipeline that integrates the ...... rs for cardiovascular disease.
@ast
A pipeline that integrates the ...... rs for cardiovascular disease.
@en
type
label
A pipeline that integrates the ...... rs for cardiovascular disease.
@ast
A pipeline that integrates the ...... rs for cardiovascular disease.
@en
prefLabel
A pipeline that integrates the ...... rs for cardiovascular disease.
@ast
A pipeline that integrates the ...... rs for cardiovascular disease.
@en
P2093
P2860
P356
P1433
P1476
A pipeline that integrates the ...... ers for cardiovascular disease
@en
P2093
Dongxiao Shen
Gregory D Lewis
Hasmik Keshishian
Laurie A Farrell
Marc S Sabatine
Michael A Fifer
Michael A Gillette
Michael Burgess
Robert E Gerszten
Steven A Carr
P2860
P2888
P304
P356
10.1038/NBT.1899
P577
2011-06-19T00:00:00Z